Why Bio-Rad Laboratories Stock Slipped by More Than 3% on Thursday

The market didn't react positively to the diagnostics specialist's third-quarter earnings report. It beat on both the top and bottom lines, but growth rates were low.

The Motley Fool • Oct 30, 2025

Bio-Rad's Q3 Earnings Miss Estimates, Revenues Surpass, Stock Falls

BIO's Q3 earnings fall short of estimates despite higher revenues, as margin pressure and weak research demand weigh on results.

Zacks Investment Research • Oct 30, 2025

Bio-Rad Laboratories, Inc. (BIO) Q3 2025 Earnings Call Transcript

Bio-Rad Laboratories, Inc. ( BIO ) Q3 2025 Earnings Call October 29, 2025 5:00 PM EDT Company Participants Yong Chung - Vice President of Investor Relations Jonathan DiVincenzo - President & COO Roop Lakkaraju - Executive VP & CFO Norman Schwartz - Chairman & CEO Conference Call Participants Patrick Donnelly - Citigroup Inc., Research Division Daniel Leonard - UBS Investment Bank, Research Division Brandon Couillard - Wells Fargo Securities, LLC, Research Division Tycho Peterson - Jefferies LLC, Research Division Jack Meehan - Nephron Research LLC Presentation Operator Ladies and gentlemen, thank you for standing by. My name is Desiree, and I will be your conference operator today.

Seeking Alpha • Oct 29, 2025

Bio-Rad Reports Third-Quarter 2025 Financial Results

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the third quarter ended September 30, 2025. “During the third quarter, we continued to navigate a dynamic global environment and evolving conditions across the markets for our life science and clinical diagnostics products," stated Norman Schwartz, Bio-Rad's Chairman and CEO. "Despite ongoing challe.

Business Wire • Oct 29, 2025

Bio-Rad Laboratories (BIO) Q3 Earnings Miss Estimates

Bio-Rad Laboratories (BIO) came out with quarterly earnings of $2.26 per share, missing the Zacks Consensus Estimate of $2.3 per share. This compares to earnings of $2.01 per share a year ago.

Zacks Investment Research • Oct 29, 2025

7 Stocks Taking The Next Step To Be On Offense

Bio-Rad Laboratories was a positive contributor after the company reported steadier earnings than the market expected. PVH also remains our largest share repurchaser for the year after buying a teens percentage of shares outstanding at great prices. Rayonier was an immediate contributor.

Seeking Alpha • Oct 23, 2025

Compelling Value In Small-Cap Equities And Select Cyclicals

Supplier of residential thermal, comfort and security solutions, Resideo Technologies, Inc. (REZI) was the top contributor in the quarter. Shares of gold mining company, Barrick Mining Corporation (B) also jumped in the quarter on strong financial results buoyed by rising gold prices. We added Arthur J. Gallagher & Co. (AJG), the world's largest insurance broker focused on middle-market clients.

Seeking Alpha • Oct 24, 2025

Bio-Rad Laboratories (BIO) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Bio-Rad (BIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research • Oct 22, 2025

It's time to scoop up undervalued stocks in this critical sector of the economy

Expanding your horizons and considering neglected sectors can help you identify bargain opportunities while defending your investment portfolio from a stock-market decline.

Market Watch • Oct 21, 2025

Bio-Rad to Report Third Quarter 2025 Financial Results on Wednesday, October 29, 2025

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, will report its financial results for the third quarter of 2025 on Wednesday, October 29, 2025, following the close of the market. Management will discuss these results in a conference call scheduled for 2:00 PM Pacific Time (5:00 PM Eastern Time) that day. To participate, dial (800) 715-9871 within the U.S. or (646) 307-1963 outside th.

Business Wire • Oct 16, 2025